- Home
- About mondoBIOTECH
- Investors
- Corporate Fact Sheet
- Company Presentation
- All Reports
- Corporate Governance
- Share Information
- Financial Calendar
- Shareholders’ Meeting
- Investor Relation Contact
- Media Releases
- Business Partners
- Pipeline
- Community
- Careers
- Contact Us
| Investors - Media Releases | ||
| Stay Informed | ||
|
2007
| ||
| December 20, 2007 |
| mondoBIOTECH forms business alliance with IFE Europe GmbH |
Basel/Essen – mondoBIOTECH AG, the Technology Pioneer 2008, today announced a new business alliance with IFE Europe GmbH, a company owned by Pierrel S.p.A., for clinical study management of trials emerging from mondoBIOTECH's product pipeline. Under the terms of the agreement, IFE Europe GmbH will provide mondoBIOTECH with full clinical trial services in support of a variety of clinical Phase 2 studies in rare diseases. The contract has an anticipated value of 1 millions Euros for IFE Europe GmbH and Pierrel S.p.A., with a potential value of up to 70 millions Euros. |
| December 10, 2007 |
| LungRx and mondoBIOTECH, the World Economic Forum Technology Pioneer 2008, signed a transatlantic strategic partnership agreement for developing drugs for patients with rare diseases |
| Silver Spring/Basel, 10 December 2007 – A major advance has been made on this International Human Rights Day 2007 for the Human Rights of patients affected by rare diseases. Lung Rx, a wholly-owned subsidiary of United Therapeutics Corporation, and mondoBIOTECH created a transatlantic strategic partnership focused on helping patients battling orphan diseases. The agreement on delivery of peptide drugs has an anticipated value of $55 Million for mondoBIOTECH, excluding royalties and other more contingent rights and agreements. The agreement provides Lung Rx with a large pipeline of products to treat orphan lung diseases as well as other diseases that are optimally treated by inhaling peptides. |
| November 29, 2007 |
| mondoBIOTECH selected as Technology Pioneer 2008 by the World Economic Forum |
The World Economic Forum today announced 39 visionary companies selected as Technology Pioneers 2008. Mondobiotech has been selected as one of these Technology Pioneers. The Technology Pioneers 2008 were nominated by the world’s leading technology experts, including venture capitalists, technology companies, academics and media. |
| November 28, 2007 |
| World Economic Forum Technology Pioneer: Mondobiotech selected |
| Switzerland 29 November 07 |
| October 19, 2007 |
| European Commission grants mondoBIOTECH's product Aviptadil the Orphan Medicinal Product Designation for the treatment of Sarcoidosis in European Union |
| Basel Switzerland, October 19, 2007. mondoBIOTECH, a private Swiss biotechnology company, today announced the receipt of an Orphan Medicinal Product Designation (OMPD) by the European Commission for its product Aviptadil for the treatment of Sarcoidosis in the European Union (EU/3/07/473), after the positive opinion given by the European Medicinal Agency (EMEA). |
| July 18, 2007 |
| mondoBIOTECH Appoints Dr. Amer Jaber as Chief Development Officer |
Basel, Switzerland, July 18, 2007 - the group mondoBIOTECH today announced the appointment of Dr. Amer Jaber to the role of Chief Development Officer. Amer will be responsible for the group’s drug development leadership on a global basis. |
| June 26, 2007 |
| The gene encoding mondoBIOTECH’s product Aviptadil discovered as ''Anti-Pulmonary Hypertension'' Gene in Mice |
| Basel, Switzerland / Stony Brook, N.Y., June 26, 2007 - A researcher team led by Prof. Sami I Said at the Stony Brook University Medical Center has identified the Vasoactive Intestinal Peptide (VIP – also known as Aviptadil) gene as an "anti-pulmonary hypertension" gene. |
| June 22, 2007 |
| mondoBIOTECH is the Best Innovator 2007: the third prize in three years won by the company and by its Chief Business Architect Fabio Cavalli. |
| Basel, June 22, 2007 - mondoBIOTECH has been awarded as the Best Innovator 2007 in Switzerland for its innovative business model. The Prize has been organized in ten European countries by A.T. Kearney, in cooperation with BILANZ for Switzerland. |
